DelveInsight, “Liver Cancer Pipeline Insight 2024” report provides comprehensive insights about 70+ Liver Cancer companies and 75+ pipeline drugs in the Liver Cancer pipeline landscape. It covers the Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Liver Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Liver Cancer Pipeline Outlook
Key Takeaways from the Liver Cancer Pipeline Report
Stay ahead with the most recent pipeline outlook for Liver Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Liver Cancer Approved Drugs
Liver Cancer Emerging Drugs Profile
Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson’s mechanism of action is mediated via deregulation of the NF-κB and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation.
YIV-906 (also PHY906 or KD018) is a therapeutic candidate comprised of a proprietary cGMP botanical extract of four herbs inspired by a traditional Chinese medicine formulation used for over a millennium. YIV-906 has the potential to be developed as a platform oncology therapeutic when administered in combination with chemotherapy, immunotherapy and radiation therapies, in multiple cancer indications. YIV-906 has been shown to enhance immune function in the tumor microenvironment (by polarizing M1 macrophages and activating T cells), protect the gastrointestinal tract (by inhibiting inflammation via IL-6, NF-kappa-B, COX2, and iNOS pathways) and promote intestinal tissue repair (by increasing activity and expression of components of the Wnt signaling pathway). YIV-906 has been observed to enhance the anti-tumor activity of sorafenib in preclinical models of hepatocellular carcinoma and has shown promise in preliminary clinical studies in liver, pancreatic, colorectal and rectal cancers. Currently, the drug is in Phase II stage of its clincal trial for the treatment of liver cancer.
TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in attenuating pY705-STAT3 phosphorylation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. Currently, the drug is in the Phase II stage of clinical trial.
STP707, our second key product, is in early-stage development for the treatment of solid tumors, liver cancer. STP707 is an intravenously administered TGF-ß1 and COX-2 inhibitor that leverages an RNAi-based response using the company’s proprietary PNP delivery platform. Currently, the drug is in Phase I stage of its clinical trial for the treatment of liver cancer.
Explore groundbreaking therapies and clinical trials in the Liver Cancer Pipeline. Access DelveInsight’s detailed report now! @ Liver Cancer Treatment Drugs
Liver Cancer Companies
Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others.
Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Liver Cancer Products have been categorized under various Molecule types such as
Unveil the future of Liver Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Liver Cancer Market Drivers and Barriers
Scope of the Liver Cancer Pipeline Report
Get the latest on Liver Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Liver Cancer Companies, Key Products and Unmet Needs
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/